Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2002
09/19/2002US20020133023 Antitumor agents, osteoporosis
09/19/2002US20020133022 Bactericides; grampositive bacteria
09/19/2002US20020133021 Bactericides
09/19/2002US20020133019 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition
09/19/2002US20020133018 Calcium channel blockers; cardiovascular disorders; side effect reduction
09/19/2002US20020133017 Chromatographic separation of enantiomers of lactones
09/19/2002US20020133016 Hypoglycemic agents; antilipemic agents; antidiabetic agents
09/19/2002US20020133012 Therapy for neurokinin sensitive disease
09/19/2002US20020133011 Alcoholism, psychological disorders
09/19/2002US20020133010 Epoxidation; quaternization
09/19/2002US20020133009 Method for opening potassium channels
09/19/2002US20020133006 Nucleophilic replacement
09/19/2002US20020132995 Modulation of immune response to preferential nucleotide sequences; obtain nucleotide sequence sample, insert adjusted nucleotides, administer to mammals monitor immune response
09/19/2002US20020132858 Method for treating sexual disorders
09/19/2002US20020132857 Administering an effective amount of a tramadol material to a human male prior to sexual intercourse.
09/19/2002US20020132856 Treatment of premenstrual syndrome
09/19/2002US20020132855 Or salts, esters or ethers of acetaminophen to prevent and treat arteriosclerosis and atherosclerosis
09/19/2002US20020132854 Long acting antidepressant microparticles
09/19/2002US20020132853 Diaryl piperazines and related compounds useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence.
09/19/2002US20020132852 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use
09/19/2002US20020132850 Multilayer tablet for administering a fixed combination of tramadol and diclofenac
09/19/2002US20020132849 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
09/19/2002US20020132847 Inhibition of TNF-alpha-initiated neutrophil response
09/19/2002US20020132846 Use of gamma substituted gamma-butyrolactones to increase levels of their corresponding substituted gamma-hydroxybutyrate derivatives in humans
09/19/2002US20020132845 Compositions and methods for the prevention and treatment of tissue ischemia
09/19/2002US20020132844 Substituted pyrazole compounds useful for the treatment of mammalian infertility.
09/19/2002US20020132843 Inhibiting intracellular replication of a parasite that possesses endogenous mitogen activated protein parasite that possesses endogenous mitogen activated protein kinase activity, by contact with a substituted imidazole
09/19/2002US20020132842 Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them
09/19/2002US20020132840 Treating angina in a mammal by administering an angiotensin II receptor antagonist.
09/19/2002US20020132839 Are at least 1.2 times more bioavailable than conventional valsartan capsule.
09/19/2002US20020132836 Compounds and methods for modulating CCR4 function
09/19/2002US20020132835 Treatment of Infant Respiratory Distress Syndrome or Adult Respiratory Distress Syndrome by administering a combination of a phospholipid lung surfactant with N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide
09/19/2002US20020132833 Caspase inhibitors and uses thereof
09/19/2002US20020132832 Administering a compound which attenuates RhoA and/or Rho-kinase activity in an organ subject to sexual stimulation to treat male and female sexual dysfunction
09/19/2002US20020132830 Use of beta 2 bronchodilator drugs
09/19/2002US20020132829 Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
09/19/2002US20020132828 N-substituted-4-(m-hydroxyphenyl)piperidine derivated and esters thereof, used to bind a kappa opioid receptor; treating drug addiction
09/19/2002US20020132827 Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, "off-period."
09/19/2002US20020132825 Analgesic combination of oxycodone and celecoxib
09/19/2002US20020132824 1,5-methylene-3-benzazepines used in treatment of neurological and psychological disorders,especially withdrawl from nicotine addiction
09/19/2002US20020132823 Assay method
09/19/2002US20020132822 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
09/19/2002US20020132821 Novel heteroaryl derivatives and their use as medicaments
09/19/2002US20020132820 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
09/19/2002US20020132818 Thienopyrimidines
09/19/2002US20020132817 Heterocyclic compounds, their production and use
09/19/2002US20020132816 Estrogen agonists/antagonists for preventing breast cancer
09/19/2002US20020132815 Anti-hypertensive composition and methods of treatment
09/19/2002US20020132814 AcrAB-like efflux pumps control resistance to drugs, even in highly resistant microbes; combination of an inhibitor of an AcrAB-like efflux pump and an antibiotic
09/19/2002US20020132811 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
09/19/2002US20020132810 Novel heterocyclic amide derivatives
09/19/2002US20020132809 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production
09/19/2002US20020132808 Useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic; also are useful as anticancer agents.
09/19/2002US20020132807 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
09/19/2002US20020132806 Treatment of atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X
09/19/2002US20020132805 Containing about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, including salts such as disodium EDTA; especially the antihistamines loratadine, descarboethoxyloratadine, and azatadine
09/19/2002US20020132803 Fluticasone propionate, an antimicrobial preservative, a surfactant, a tonicity agent, and a suspending agent; pump spray devices.
09/19/2002US20020132802 Cytoprotective polycyclic compounds
09/19/2002US20020132801 Along with an estrogen, such as estradiol or estradiol valerate
09/19/2002US20020132798 7-phenyl-substituted tetracycline compounds
09/19/2002US20020132797 DNA-cleaving antitumor agents
09/19/2002US20020132796 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid.
09/19/2002US20020132795 Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds
09/19/2002US20020132794 Compounds and methods for inhibition of HIV and related viruses
09/19/2002US20020132793 Use of methylphenidate compounds to enhance memory
09/19/2002US20020132791 Beta-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
09/19/2002US20020132790 Pharmaceutical compositions for topical use containing hyaluronic acid and its derivatives
09/19/2002US20020132787 Compositions and methods for nucleic acid delivery to the lung
09/19/2002US20020132784 Cytokine related treatments of disease
09/19/2002US20020132781 Optionally a glutathione pathway enhancing and detoxifying compound, particularly cystine
09/19/2002US20020132778 Modulating angiogenesis
09/19/2002US20020132770 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
09/19/2002US20020132764 Cyclosporin; mycophenolic acid or its salt as an immunosuppressor; and rapamycin or a derivative
09/19/2002US20020132761 Glycoprotein matrix bound to a biologically active ingredient, especially a vitamin, mineral, or L-Carnitine base; optionally contains a bioflavonoid, a yeast and/or a bacterium
09/19/2002US20020132754 Producing pharmaceuticals for improving perception, concentration, learning and/or memory.
09/19/2002US20020132753 Nucleic acids, proteins, and antibodies
09/19/2002US20020132337 Processes for preparation of marek's disease virus using continuous avian cell lines
09/19/2002US20020132319 Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof
09/19/2002US20020132306 Premature antihemopliic factor; for use in the treatment of blood disorders
09/19/2002US20020132296 Human Ste20-like stress activated serine/threonine kinase
09/19/2002US20020132279 Adjusting glucose concentration in humans; obtain carbohydrate sufficient to adjust blood glucose, ingest, monitor blood glucose concentration
09/19/2002US20020132237 Detecting ovarian cancer humans; obtain sample, incubate with preferential oligonucleotides, monitor hybridization, compare to control, evaluate for cancer
09/19/2002US20020132224 CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
09/19/2002US20020132223 Methods for modulating activity of the FXR nuclear receptor
09/19/2002US20020132219 Composition and method for modulating nutrient partitioning
09/19/2002US20020132030 Edible microbiocide of .05-1.0% alkyl paraben, and .1-.2% benzoic and sorbic acids salts
09/19/2002US20020132019 Sterol fractions of Nigella sativa L. seeds
09/19/2002US20020132018 Use of non-alkalized cocoa solids in a drink
09/19/2002US20020132015 Compositions and methods for high sorption of skin materials and delivery of sulfur
09/19/2002US20020132014 Administering amounts of calcium to induce a metabolic change; inducing the loss of adipose tissue; stimulating lipolysis, inhibiting lipogenesis, and increasing the expression of white adipose tissue uncoupling protein 2 (UCP2)
09/19/2002US20020132011 Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
09/19/2002US20020132010 Divalproex sodium dosage forms and a process for their production
09/19/2002US20020132009 Entacapone, nitecapone, or salts thereof and croscarmellose sodium to increase the release rate; catechol-O-methyl transferase inhibitors
09/19/2002US20020132004 Anti-inflammatory pharmaceutical formulations
09/19/2002US20020132001 Delayed-release formulation of aldosterone antagonist drug which when orally administered 6-12 hours prior to acrophase provides profile of plasma drug concentration corresponding to diurnal cycle of plasma aldosterone concentration
09/19/2002US20020131999 Using stearic acid or zinc stearate as lubricant
09/19/2002US20020131998 Rapidly dissolving dosage form and process for making same
09/19/2002US20020131997 Method for treating hematologic disorders with water insoluble 20 (S)-camptothecin
09/19/2002US20020131996 Methods and compositions for blocking microbial adherence to eukaryotic cells
09/19/2002US20020131993 Gel, ointment, solution, suspension or film containing mixture of nicotine and an uncrosslinked, water-insoluble vinypyrrolidone copolymer with hydrophobic comonomer for sustained transdermal delivery of nicotine; smoking-cessation